Anti-ROR1 antibody and ROR1-targeting engineered cells
Inventors
Golubovskaya, Vita • Wu, Lijun
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present invention is directed to a monoclonal mouse or humanized ROR1 antibody, or a single-chain variable fragment (scFv). The present invention is also directed to a mouse or humanized ROR1 chimeric antigen receptor (CAR) comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain.
Core Innovation
The invention relates to anti-human ROR1 monoclonal antibodies and antigen-binding fragments that bind ROR1 and include defined complementarity determining regions within variable heavy and variable light regions. The antibodies or antigen-binding fragments comprise a VH amino acid sequence that is at least 90% identical to SEQ ID NO: 2 and a VL amino acid sequence that is at least 90% identical to SEQ ID NO: 3.
The VH and VL CDRs are specified such that the VH CDR1 comprises the sequence TYA, the VH CDR2 comprises SEQ ID NO: 41, the VH CDR3 comprises SEQ ID NO: 42, the VL CDR1 comprises SEQ ID NO: 43, the VL CDR2 comprises the sequence RAN, and the VL CDR3 comprises SEQ ID NO: 45. The invention further encompasses engineered binding formats and constructs derived from the anti-ROR1 antibodies, including single-chain variable fragment (scFv) formats and humanized variants.
Defined scFv constructs and their sequence constraints are incorporated into a chimeric antigen receptor (CAR) architecture. The CAR architecture is described as an scFv–transmembrane domain–co-stimulatory domain (CD28 or 4-1BB)–activation domain (CD3ζ), including additional structural elements such as a hinge domain and signaling elements.
The document reports experimental validation of ROR1 binding and functional activity for the anti-ROR1 scFv-based CAR designs, including comparisons between different CAR co-stimulatory domains and between mouse and humanized scFv variants. Antibody binding to ROR1 is supported by Western blot, and ROR1 detection on ROR1-positive cells is supported by FACS.
Claims Coverage
The independent claims cover 1 inventive feature for a defined anti-human ROR1 antibody or antigen-binding fragment, and extend to derivative binding formats and engineered CAR constructs with defined signaling architecture.
Defined anti-human ROR1 antibody with VH/VL identity and specified CDR sequences
An anti-human ROR1 antibody or an antigen-binding fragment comprising VH with an amino acid sequence at least 90% identical to SEQ ID NO: 2 and VL with an amino acid sequence at least 90% identical to SEQ ID NO: 3, wherein a CDR1 of the VH comprises the sequence TYA, a CDR2 of the VH comprises SEQ ID NO: 41, a CDR3 of the VH comprises SEQ ID NO: 42, a CDR1 of the VL comprises SEQ ID NO: 43, a CDR2 of the VL comprises the sequence RAN, and a CDR3 of the VL comprises SEQ ID NO: 45.
The claims focus on precise definition of anti-human ROR1 binding specificity through VH/VL sequence identity thresholds and explicit CDR composition constraints, and extend this into scFv and CAR constructs with defined domain architecture and co-stimulatory domain options.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?